Improved immunogenicity and protective efficacy of a replicon DNA vaccine encoding the Hc domain of botulinum neurotoxin serotype A by electric pulses and protein boosting

References

• Turton, K., Chaddock J.A., Acharya K.R. Botulinum and tetanus neurotoxtins: structure, function and therapeutic utility. Trends Biochem. Sci. 2002, 27, 552–558.
   PubMed Web of Science ®Google Scholar
• Schiavo, G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol. Rew. 2000, 80, 717–766.
   PubMed Web of Science ®Google Scholar
• Byrne, M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82, 955–966.
   PubMed Web of Science ®Google Scholar
• Clayton, M.A., Clayton, J.M., Brown, D.R., Middlebrook J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect. Immun. 1995, 63, 2728–2742.
   Web of Science ®Google Scholar
• Byrne, M.P., Smith T.J., Montgomery V.A., Smith L.A. Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate. Infect. Immun. 1998, 66, 4817–22.
   PubMed Web of Science ®Google Scholar
• Baldwin, M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., Fritz R.B., Johnson E.A., Barbieri J.T. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect. Immun. 2005, 73, 6998–7005.
   PubMed Web of Science ®Google Scholar
• Middlebrook, J.L. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Adv. Drug Deliv. Rev. 2005, 57, 1415–1423.
   Google Scholar
• Clayton, J., Middlebrook J.L. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine 2000, 18, 1855–1862.
   PubMed Web of Science ®Google Scholar
• Shyu, R.H., Shaio M.F., Tang, S.S., Shyu, H.F., Lee C.F., Tsai M.H., Smith J.E., Huang H.H., Wey J.J., Huang J.L., Chang H.H. DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice. J Biomed. Sci. 2000, 7, 51–57.
   Google Scholar
• Bennett, A.M., Perkins S.D., Holley J.L. DNA vaccination protects against botulinum neurotoxin type F. vaccine 2003, 21, 3110–3117.
   PubMed Web of Science ®Google Scholar
• Jathoul, A.P., Holley J.L., Garmory H.S. Efficacy DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters. Vaccine 2004, 22, 3942–3946.
   PubMedGoogle Scholar
• Lee, J.S., Pushko P., Parker M.D., Dertzbaugh M.T., Smith L.A., Smith J.F. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect. Immun. 2001, 69, 5709–5715.
   PubMed Web of Science ®Google Scholar
• Lee, J.S., Groebner J.L., Hadjipanayis A.G., Negley D.L., Schmaljohn A.L., Welkos S.L., Smith L.A., Smith J.F. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 2006, 24, 6886–6892.
   PubMed Web of Science ®Google Scholar
• Ulmer, J.B., Wahren B., Liu M.A. Gene-based vaccines: recent technical and clinical advances. Trends Mol. Med. 2006, 12, 216–222.
   PubMed Web of Science ®Google Scholar
• Dhama, K., Mahendran M., Gupta P.K., Rai A. DNA vaccines and their applications in veterinary practice: current perspectives. Vet. Res. Commun. 2008, 32, 341–356.
   PubMed Web of Science ®Google Scholar
• Yu, Y.Z., Zhang S.M., Sun Z.W., Wang S., Yu W.Y. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A Vaccine 2007, 25, 8843–8850.
   PubMed Web of Science ®Google Scholar
• Yu, Y.Z., Sun Z.W., Li Na., Wang S., Wang R.L., Yu W.Y. Protection with a recombinant Hc of Clostridium Botulinum neurotoxin serotype A from Escherichia coli as an effective subunit vaccine. Immunopharmacol. Immunotoxicol. DOI: 10.1080/08923970802438433.
   Google Scholar
• Lu, S., Wang, S., Grimes-Serrano, J.M. Current progress of DNA vaccine studies in humans. Expert Rev. Vaccines 2008, 7, 175–191.
   Google Scholar
• Trollet, C., Bloquel, C., Scherman, D., Bigey, P. Electrotransfer into skeletal muscle for protein expression.Curr. Gene Ther. 2006, 6, 561–578.
   Google Scholar
• Cemazar, M., Sersa G. Electrotransfer of therapeutic molecules into tissues. Curr Opin. Mol. Ther. 2007, 9, 554–562.
   PubMedGoogle Scholar
• Bloquel, C., Fabre E., Bureau M.F., Scherman D. Plasmid DNA electrotransfer for intracellular and secreted proteins expression: new methodological developments and applications. J. Gene Med. 2004, 6, S11–S23.
   PubMed Web of Science ®Google Scholar
• Grønevik, E., von Steyern, F.V., Kalhovde J.M., Tjelle, T.E., Mathiesen, I. Gene expression and immune response kinetics using electroporation-mediated DNA delivery to muscle. J. Gene Med. 2005, 7, 218–227.
   PubMed Web of Science ®Google Scholar
• Otten, G., Schaefer M., Doe B., Liu H., Srivastava I., zur Megede J., O’Hagan D., Donnelly J., Widera G., Rabussay D., Lewis M.G., Barnett S., Ulmer J.B. Enhancement of DNA vaccine potency in rhesus macaques by electroporation. Vaccine 2004, 22, 2489–2493.
   PubMed Web of Science ®Google Scholar
• Otten, G.R., Schaefer M., Doe B., Liu H., Megede J.Z., Donnelly J., Rabussay D., Barnett S., Ulmer J.B. Potent immunogenicity of an HIV-1 gag-pol fusion DNA vaccine delivered by in vivo electroporation. Vaccine 2006, 24, 4503–4509.
   PubMed Web of Science ®Google Scholar
• Luckay, A., Sidhu M.K., Kjeken R., Megati S., Chong S.Y., Roopchand V., Garcia-Hand D., Abdullah R., Braun R., Montefiori D.C., Rosati M., Felber B.K., Pavlakis G.N., Mathiesen I., Israel Z.R., Eldridge J.H., Egan M.A. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J. Virol. 2007, 81, 5257–5269.
   PubMed Web of Science ®Google Scholar
• Tjelle, T.E., Salte R., Mathiesen I., Kjeken R. A novel electroporation device for gene delivery in large animals and humans. Vaccine 2006, 24, 4667–4670.
   PubMed Web of Science ®Google Scholar
• Tjelle, T.E., Rabussay D., Ottensmeier C., Mathiesen I., Kjeken R. Taking electroporation-based delivery of DNA vaccination into humans: a generic clinical protocol. Methods Mol. Biol. 2008, 423, 497–507.
   PubMedGoogle Scholar
• Bhardwaj, D., Kushwaha A., Puri S.K., Herrera A., Singh N., Chauhan V.S. DNA prime-protein boost immunization in monkeys: efficacy of a novel construct containing functional domains of Plasmodium cynomolgi CS and TRAP. FEMS Immunol. Med. Microbiol. 2003, 39, 241–250.
   Google Scholar
• Leung, L., Srivastava I.K., Kan E., Legg H., Sun Y., Greer C., Montefiori D.C., zur Megede J., Barnett S.W. Immunogenicity of HIV-1 Env and Gag in baboons using a DNA prime/protein boost regimen. AIDS 2004, 18, 991–1001.
   Google Scholar
• Li, Z., Zhang H., Fan X., Zhang Y., Huang J., Liu Q., Tjelle T.E., Mathiesen I., Kjeken R., Xiong S. DNA electroporation prime and protein boost strategy enhances humoral immunity of tuberculosis DNA vaccines in mice and non-human primates. Vaccine 2006, 24, 4565–4568.
   PubMed Web of Science ®Google Scholar